Equity Overview
Price & Market Data
Price: $25.05
Daily Change: -$1.37 / 5.47%
Range: $24.65 - $26.49
Market Cap: $276,945,280
Volume: 222,414
Performance Metrics
1 Week: -1.38%
1 Month: 15.44%
3 Months: -8.79%
6 Months: 47.35%
1 Year: 140.9%
YTD: 108.8%
Company Details
Employees: 14
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania